Polyphenols taken from three sorghum varieties reduced amyloid-beta aggregation, improved cell survival and increased mitochondrial activity in cultured human brain cells, but researchers said animal and human studies are still required.
By yourNEWS Media Newsroom
Polyphenols extracted from sorghum significantly reduced the accumulation of an Alzheimer’s-associated protein and strengthened several protective functions in cultured human brain cells, according to early laboratory research published this month in the journal Nutrients.
The strongest results came from black sorghum, one of three varieties examined in the study. Extracts from black, red-brown and red sorghum reduced the aggregation of amyloid-beta by approximately 67% to 76%, with black sorghum producing the greatest effect.
Amyloid-beta is a sticky protein that can accumulate in the brain and form plaques associated with Alzheimer’s disease. Although the protein remains an important focus of research, scientists increasingly recognize that the disease also involves inflammation, oxidative damage, impaired energy production and other cellular disruptions.
The sorghum extracts appeared to influence several of those processes at once. Treated cells recorded more than a 70% improvement in survival, while activity within their mitochondria increased by roughly 80%.
Mitochondria generate much of the energy cells need to function. Damage to those structures can weaken brain cells and has been linked to the progression of several neurodegenerative conditions.
Researchers also found that the extracts sharply reduced oxidative stress, activated genes associated with cellular protection and suppressed pathways connected to inflammation. One affected pathway was associated with iron-driven cell death.
The findings suggest sorghum polyphenols may provide broad cellular protection rather than acting only against amyloid-beta. That distinction could be important because Alzheimer’s disease involves several interacting biological processes rather than a single abnormal protein.
Scientists produced the extracts by isolating polyphenols from the three sorghum varieties and applying concentrated amounts directly to cultured human brain cells. The cells were then exposed to amyloid-beta so investigators could measure whether the plant compounds limited protein aggregation and reduced cellular damage.
Black sorghum consistently delivered the strongest protection among the varieties tested. Researchers attributed the difference to its higher concentration and distinctive composition of polyphenols, plant compounds known for antioxidant and anti-inflammatory activity.
Polyphenols are also present in berries, tea, olive oil, dark chocolate and numerous other plant foods. Previous research has examined whether diets rich in those compounds may support brain health and reduce inflammation associated with aging.
Sorghum has been consumed for centuries across Africa and Asia, where it remains an important staple crop. The naturally gluten-free grain provides fiber and several nutrients, but it is less familiar to many American consumers than wheat, rice, corn or oats.
Its agricultural characteristics have also attracted attention. Sorghum is drought-resistant and reportedly requires 36% less water than other grains. More than 90% of sorghum acreage in the United States depends primarily on rainfall rather than irrigation, according to the United Sorghum Checkoff Program.
Those qualities could make sorghum an economical source of plant compounds for future research, particularly in regions where water availability and food costs are major concerns.
The laboratory results do not demonstrate that eating sorghum can prevent, treat or reverse Alzheimer’s disease. Researchers used concentrated extracts applied directly to cells, a process substantially different from consuming cooked grain as part of a meal.
After food is eaten, its compounds must survive digestion, enter the bloodstream and reach relevant tissues in sufficient concentrations. Any substance intended to affect the brain must also cross or otherwise influence the blood-brain barrier.
The study did not determine whether sorghum polyphenols can complete those steps, nor did it establish what quantity of sorghum a person would need to consume to reproduce the effects seen in cultured cells.
The authors characterized the research as “an important early step” and said “in vivo studies… to establish efficacy” are needed before health claims can be made.
Animal testing would generally be required before researchers could determine whether the extracts reach the brain, remain biologically active and produce similar protective effects within a living organism. Human clinical trials would then be necessary to evaluate safety, dosage and effectiveness.
The findings arrive as scientists continue searching for more effective ways to prevent or slow cognitive decline. Established Alzheimer’s medications such as donepezil and memantine are used primarily to manage symptoms and may provide temporary improvements in memory or daily functioning for some patients.
The study’s authors did not propose sorghum as a replacement for those medications or for professional medical care. Instead, the research identifies naturally occurring compounds that may warrant further investigation as possible tools for protecting brain cells.
Sorghum’s availability and low production costs could become important if future research confirms that its polyphenols have meaningful biological effects. Plant-derived compounds may also offer opportunities to develop dietary strategies or treatments that operate through multiple protective mechanisms.
Claims that sorghum is entirely free of side effects cannot be established from a cell study. Whole sorghum is commonly consumed as food, but concentrated extracts could behave differently and would require formal safety testing before therapeutic use.
The research nevertheless provides a basis for examining whether sorghum’s polyphenols can reduce amyloid accumulation, improve mitochondrial function and limit inflammation in animals and eventually in people.
For consumers, sorghum can be incorporated into a balanced diet as a whole grain, but the present evidence does not support using it as an Alzheimer’s treatment. Eating the grain is not equivalent to exposing brain cells directly to concentrated laboratory extracts.
The broader significance of the findings lies in the possibility that food-derived compounds could influence several pathways associated with neurodegeneration. If later studies reproduce the results in living organisms, sorghum could become a useful subject in efforts to develop affordable approaches to preserving brain health.
Until those studies are completed, the reported reduction in amyloid-beta remains an encouraging laboratory observation rather than evidence of a clinical benefit. Researchers said the next steps must determine whether the cellular protection seen in the experiment can be achieved safely through diet, supplements or other formulations.
Source: Natural News
Original article
Comments